; or ; and (C) by adding at the end the following: (iii) accommodate different approved risk evaluation and mitigation strategies for a reference drug product and a drug that is the subject of an abbreviated new drug application. ; and (2) in subsection (i)(1), by striking subparagraph (B) and inserting the following: (B) Elements to assure safe use, if required under subsection (f) for the listed drug in accordance with the following: (i) Subject to clause (ii), a drug that is the subject of an abbreviated new drug application may use— (I) a single, shared system with the listed drug under subsection (f)